Fierce Biotech May 3, 2024
Delegates at the LSX World Conference in London this week seemed to agree on one thing—the biotech IPO window finally re-opened this year. This sentiment has persisted despite the fact that the initial run of public offerings died down by the spring.
For Francesco De Rubertis, co-founder and partner of London-based life sciences investment firm Medicxi, the current lull is to be expected. What’s more, he expects “at least a number of IPOs” to arrive as soon as the summer.
“In the absence of other external [factors], the natural dynamics of markets should say that now there will be another big number of investors that will become active on the public markets, and that will translate in the next wave...
Today's Sponsors
Today's Sponsor